Disagreement between human papillomavirus assays: An unexpected challenge for the choice of an assay in primary cervical screening

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Rebolj, Matejka ^a   Preisler, Sarah ^b   Ejegod, Ditte Møller ^b   Rygaard, Carsten ^b   Lynge, Elsebeth ^a   Bonde, Jesper ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DENMARK; FEMALE; GYNECOLOGICAL EXAMINATION; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; INTERMETHOD COMPARISON; MIDDLE AGED; NONHUMAN; PRIMARY CERVICAL SCREENING; PROBABILITY; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION; WART VIRUS; YOUNG ADULT;

ADULT; AGED; BIOLOGICAL ASSAY; DENMARK; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; YOUNG ADULT;

EID: 84906932041     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0086835     Document Type: Article

References (33)

1. Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, et al. (2008) Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 337: a1754.
2. Berkhof J, Coupé VM, Bogaards JA, van Kemenade FJ, Helmerhorst TJ, et al. (2010) The health and economic effects of HPV DNA screening in The Netherlands. Int J Cancer 127: 2147-2158.
3. Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJ, et al. (2013) Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet (Epub ahead of print).
4. Clad A, Reuschenbach M, Weinschenk J, Grote R, Rahmsdorf J, et al. (2011) Performance of the APTIMA high-risk HPV mRNA assay in a referral population in comparison with Hybrid Capture 2 and cytology. J Clin Microbiol 49: 1071-1076.
5. Gage JC, Sadorra M, Lamere BJ, Kail R, Aldrich C, et al. (2012) Comparison of the cobas Human Papillomavirus (HPV) test with the hybrid capture 2 and linear array HPV DNA tests. J Clin Microbiol 50: 61-65.
6. Lapierre SG, Sauthier P, Mayrand MH, Dufresne S, Petignat P, et al. (2012) Human papillomavirus (HPV) DNA triage of women with atypical squamous cells of undetermined significance with cobas 4800 HPV and Hybrid Capture 2 tests for detection of high-grade lesions of the uterine cervix. J Clin Microbiol 50: 1240-1244.
7. Lindemann ML, Dominguez MJ, de Antonio JC, Sandri MT, Tricca A, et al. (2012) Analytical comparison of the cobas HPV Test with Hybrid Capture 2 for the detection of high-risk HPV genotypes. J Mol Diagn 14: 65-70.
8. Park Y, Lee E, Choi J, Jeong S, et al. (2012) Comparison of the Abbott RealTime High-Risk Human Papillomavirus (HPV), Roche Cobas HPV, and Hybrid Capture 2 assays to direct sequencing and genotyping of HPV DNA. J Clin Microbiol 50: 2359-2365.
9. Pista A, Verdasca N, Oliveira A (2011) Clinical performance of the CLART human papillomavirus 2 assay compared with the hybrid capture 2 test. J Med Virol 83: 272-276.
10. Reuschenbach M, Clad A, von Knebel Doeberitz C, Wentzensen N, Rahmsdorf J, et al. (2010) Performance of p16INK4a-cytology, HPV mRNA, and HPV DNA testing to identify high grade cervical dysplasia in women with abnormal screening results. Gynecol Oncol 119: 98-105.
11. Szarewski A, Ambroisine L, Cadman L, Austin J, Ho L, et al. (2008) Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol Biomarkers Prev 17: 3033-3042.
12. Wong AA, Fuller J, Pabbaraju K, Wong S, Zahariadis G (2012) Comparison of the hybrid capture 2 and cobas 4800 tests for detection of high-risk human papillomavirus in specimens collected in PreservCyt medium. J Clin Microbiol 50: 25-29.
13. García-Sierra N, Martró E, Castellà E, Llatjós M, Tarrats A, et al. (2009) Evaluation of an array-based method for human papillomavirus detection and genotyping in comparison with conventional methods used in cervical cancer screening. J Clin Microbiol 47: 2165-2169.
14. Stoler MH, Wright TC Jr, Sharma A, Apple R, Gutekunst K, et al. (2011) Highrisk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am J Clin Pathol 135: 468-475.
15. Ratnam S, Coutlee F, Fontaine D, Bentley J, Escott N, et al. (2011) Aptima HPV E6/E7 mRNA Test Is as Sensitive as Hybrid Capture 2 Assay but More Specific at Detecting Cervical Precancer and Cancer. J Clin Microbiol 49: 557-564.
16. Stoler MH, Wright TC Jr, Cuzick J, Dockter J, Reid JL, et al. (2013) APTIMA HPV assay performance in women with atypical squamous cells of undetermined significance cytology results. Am J Obstet Gynecol 208: 144.e1-8.
17. Ki EY, Kim HE, Choi YJ, Park JS, Kang CS, et al. (2013) Comparison of the Cobas 4800 HPV Test and the Seeplex HPV4A ACE with the Hybrid Capture 2 Test. Int J Med Sci 10: 119-123.
18. Mesher D, Szarewski A, Cadman L, Austin J, Ashdown-Barr L, et al. (2013) Comparison of human papillomavirus testing strategies for triage of women referred with low-grade cytological abnormalities. Eur J Cancer (In press).
19. Meijer CJ, Berkhof J, Castle PE, Hesselink AT, Franco EL, et al. (2009) Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 124: 516-520.
20. Monsonego J, Hudgens MG, Zerat L, Zerat JC, Syrjänen K, et al. (2011) Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: The FASE study. Int J Cancer 129: 691-701.
21. Wu R, Belinson SE, Du H, Na W, Qu X, et al. (2010) Human papillomavirus messenger RNA assay for cervical cancer screening: the Shenzhen Cervical Cancer Screening Trial I. Int J Gynecol Cancer 20: 1411-1414.
22. Heideman DA, Hesselink AT, Berkhof J, van Kemenade F, Melchers WJ, et al. (2011) Clinical validation of the cobas 4800 HPV test for cervical screening purposes. J Clin Microbiol 49: 3983-3985.
23. Cuzick J, Cadman L, Mesher D, Austin J, Ashdown-Barr L, et al. (2013) Comparing the performance of six human papillomavirus tests in a screening population. Br J Cancer 108: 908-913.
24. Lloveras B, Gomez S, Alameda F, Bellosillo B, Mojal S, et al. (2013) HPV Testing by cobas HPV Test in a Population from Catalonia. PLoS One 8: e58153.
25. Styregruppen for DKLS. Årsrapport DKLS 2011: Dansk Kvalitetsdatabase for Livmoderhalskræftscreening [Annual report 2011: Danish Quality Assurance database for cervical cancer screening]. Available: https://www.sundhed.dk/content/cms/80/1880-aarsrapport-2010- livmoderhalskraeftscreening.pdf. Accessed: 11 September 2012.
26. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, et al. (2009) A review of human carcinogens-Part B: biological agents. Lancet Oncol 10: 321-322.
27. Getman D, Aiyer A, Dockter J, Giachetti C, Zhang F, et al. (2009) Efficiency of the APTIMA HPV Assay for detection of HPV RNA and DNA targets. J Clin Virol 45: S49-S54.
28. Ramanakumar AV, Goncalves O, Richardson H, Tellier P, Ferenczy A, et al. (2010) Human papillomavirus (HPV) types 16, 18, 31, 45 DNA loads and HPV-16 integration in persistent and transient infections in young women. BMC Infect Dis 10: 326.
29. Snijders PJ, van den Brule AJ, Meijer CJ (2003) The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. J Pathol 201: 1-6. (Pubitemid 37121197)
30. Eklund C, Forslund O, Wallin KL, Zhou T, Dillner J (2012) The 2010 global proficiency study of human papillomavirus genotyping in vaccinology. J Clin Microbiol 50: 2289-2298.
31. Arbyn M, Roelens J, Cuschieri K, Cuzick J, Szarewski A, et al. (2013) The APTIMA HPV assay versus the hybrid capture 2 test in triage of women with ASC-US or LSIL cervical cytology: A meta-analysis of the diagnostic accuracy. Int J Cancer 132: 101-108.
32. Kjaer SK, Breugelmans G, Munk C, Junge J, Watson M, et al. (2008) Population-based prevalence, type- and age-specific distribution of HPV in women before introduction of an HPV-vaccination program in Denmark. Int J Cancer 123: 1864-1870.
33. Szarewski A, Mesher D, Cadman L, Austin J, Ashdown-Barr L, et al. (2012) Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: the predictors 2 study. J Clin Microbiol 50: 1867-1873.